However, serious side effects like pancreatitis and kidney problems might take some time to resolve
Obesity, hypertension, and chronic kidney disease
doi: 10.1016/S1474-4422(21)00030-2
These drugs can increase the risk of developing pancreatitis (inflammation of the pancreas)
longer cycles may use intermittent dosing schedules as tolerated [4]
Frequently Asked Questions 1STEP Trials Program: Semaglutide 2.4mg for Obesity New England Journal of Medicine, 2021 2SURMOUNT-1: Tirzepatide for Treatment of Obesity New England Journal of Medicine, 2022 3Retatrutide Phase 2 Trial Results in Obesity New England Journal of Medicine, 2023 4Comparative Efficacy of GLP-1 Receptor Agonists: A Network Meta-Analysis The Lancet Diabetes & Endocrinology, 2024 5SELECT Trial: Semaglutide Cardiovascular Outcomes New England Journal of Medicine, 2023 Related Articles Comparison Tirzepatide vs Semaglutide: Which Weight Loss Medication Works Better